ClinicalTrials.gg

Program

tanruprubart

Also written as “ANX005” and “Tanruprubart”.

Its studies are mostly in Guillain-Barre Syndrome · Huntington Disease · Anemia, Hemolytic, Autoimmune · Amyotrophic Lateral Sclerosis, led by Annexon.

Furthest: phase 3, since Jan 6, 20217 company-led studies, 1 open or runningNext primary completion: May 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Annexon71 open or runningphase 3since Jan 6, 2021Dec 21, 2016May 31, 2027phase 3 · NCT07020819

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 21, 2016First study: phase 1 study in Safety and Tolerability in Healthy VolunteersFirst studyNCT03010046 · 27 enrolled · Australia
  2. Jul 11, 2019Phase 1 study in Guillain-Barre SyndromeNCT04035135 · 14 enrolled · Bangladesh, Denmark
  3. Jul 27, 2020Phase 2 study in Huntington DiseaseNCT04514367 · 28 enrolled · United States
  4. Sep 23, 2020Phase 2 study in Amyotrophic Lateral SclerosisNCT04569435 · 17 enrolled · United States, Canada
  5. Dec 28, 2020Phase 2 study in Warm Autoimmune Hemolytic Anemia (wAIHA)NCT04691570 · 7 enrolled · United States, Australia, Austria and more
  6. Jan 6, 2021Phase 3 study in Guillain-Barre SyndromeNCT04701164 · 242 enrolled · Bangladesh, Philippines
  7. Jun 6, 2025Phase 3 study in Guillain-Barre SyndromeNCT07020819 · 30 planned · United States, Denmark, France and more

Ahead

  1. May 31, 2027Primary completion: phase 3 study in Guillain-Barre SyndromeNCT07020819

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07020819Guillain-Barre Syndrome · United States, Denmark, France and more3RecruitingMay 31, 202730
NCT04701164Guillain-Barre Syndrome · Bangladesh, Philippines3CompletedApr 20, 2024242
NCT04691570Warm Autoimmune Hemolytic Anemia (wAIHA) · United States, Australia, Austria and more2CompletedJan 17, 20237
NCT04569435Amyotrophic Lateral Sclerosis · United States, Canada2CompletedJan 10, 202417
NCT04514367Huntington Disease · United States2CompletedAug 29, 202228
NCT04035135Guillain-Barre Syndrome · Bangladesh, Denmark1CompletedMay 19, 202114
NCT03010046Safety and Tolerability in Healthy Volunteers · Australia1TerminatedJun 201827

How it is read

Names in the registry

  • “ANX005”, 6 entries
  • “Tanruprubart”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.